Multispecies-compatible antitumor effects of a cross-species small-interfering RNA against mammalian target of rapamycin

Jeonghyun Ahn, Ha Na Woo, Ara Ko, Maria Khim, Catherine Kim, Nung Hwa Park, Ho Young Song, Seong Who Kim, Heuiran Lee

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Successful development of sequence-specific siRNA (small interfering RNA)-based drugs requires an siRNA design that functions consistently in different organisms. Utilizing the CAPSID program previously developed by our group, we here designed siRNAs against mammalian target of rapamycin (mTOR) that are entirely complementary among various species and investigated their multispecies-compatible gene-silencing properties. The mTOR siRNAs markedly reduced mTOR expression at both the mRNA and protein levels in human, mouse, and monkey cell lines. The reduction in mTOR expression resulted in inactivation of both mTOR complex I and II signaling pathways, as confirmed by reduced phosphorylation of p70S6K (70-kDa ribosomal protein S6 kinase), 4EBP1 (eIF4E-binding protein 1), and AKT, and nuclear accumulation of FOXO1 (forkhead box O1), with consequent cell-cycle arrest, proliferation inhibition, and autophagy activation. Moreover, interfering with mTOR activity in vivo using mTOR small-hairpin RNA-expressing recombinant adeno-associated virus led to significant antitumor effects in xenograft and allograft models. Thus, the present study demonstrates that cross-species siRNA successfully silences its target and readily produces multispecies- compatible phenotypic alterations-antitumor effects in the case of mTOR siRNA. Application of crossspecies siRNA should greatly facilitate the development of siRNA-based therapeutic agents.

Original languageEnglish (US)
Pages (from-to)3147-3158
Number of pages12
JournalCellular and Molecular Life Sciences
Volume69
Issue number18
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Sirolimus
Small Interfering RNA
70-kDa Ribosomal Protein S6 Kinases
Dependovirus
Autophagy
Gene Silencing
Cell Cycle Checkpoints
Heterografts
Haplorhini
Allografts
Carrier Proteins
Phosphorylation
Cell Line
Messenger RNA
Pharmaceutical Preparations

Keywords

  • CAPSID
  • Cross-species activity
  • Mammalian target of rapamycin
  • Small-interfering RNA
  • Tumor therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Pharmacology
  • Cellular and Molecular Neuroscience
  • Cell Biology

Cite this

Multispecies-compatible antitumor effects of a cross-species small-interfering RNA against mammalian target of rapamycin. / Ahn, Jeonghyun; Woo, Ha Na; Ko, Ara; Khim, Maria; Kim, Catherine; Park, Nung Hwa; Song, Ho Young; Kim, Seong Who; Lee, Heuiran.

In: Cellular and Molecular Life Sciences, Vol. 69, No. 18, 01.09.2012, p. 3147-3158.

Research output: Contribution to journalArticle

Ahn, Jeonghyun ; Woo, Ha Na ; Ko, Ara ; Khim, Maria ; Kim, Catherine ; Park, Nung Hwa ; Song, Ho Young ; Kim, Seong Who ; Lee, Heuiran. / Multispecies-compatible antitumor effects of a cross-species small-interfering RNA against mammalian target of rapamycin. In: Cellular and Molecular Life Sciences. 2012 ; Vol. 69, No. 18. pp. 3147-3158.
@article{50ba85db1a054b3bac54d8099b9f897c,
title = "Multispecies-compatible antitumor effects of a cross-species small-interfering RNA against mammalian target of rapamycin",
abstract = "Successful development of sequence-specific siRNA (small interfering RNA)-based drugs requires an siRNA design that functions consistently in different organisms. Utilizing the CAPSID program previously developed by our group, we here designed siRNAs against mammalian target of rapamycin (mTOR) that are entirely complementary among various species and investigated their multispecies-compatible gene-silencing properties. The mTOR siRNAs markedly reduced mTOR expression at both the mRNA and protein levels in human, mouse, and monkey cell lines. The reduction in mTOR expression resulted in inactivation of both mTOR complex I and II signaling pathways, as confirmed by reduced phosphorylation of p70S6K (70-kDa ribosomal protein S6 kinase), 4EBP1 (eIF4E-binding protein 1), and AKT, and nuclear accumulation of FOXO1 (forkhead box O1), with consequent cell-cycle arrest, proliferation inhibition, and autophagy activation. Moreover, interfering with mTOR activity in vivo using mTOR small-hairpin RNA-expressing recombinant adeno-associated virus led to significant antitumor effects in xenograft and allograft models. Thus, the present study demonstrates that cross-species siRNA successfully silences its target and readily produces multispecies- compatible phenotypic alterations-antitumor effects in the case of mTOR siRNA. Application of crossspecies siRNA should greatly facilitate the development of siRNA-based therapeutic agents.",
keywords = "CAPSID, Cross-species activity, Mammalian target of rapamycin, Small-interfering RNA, Tumor therapeutics",
author = "Jeonghyun Ahn and Woo, {Ha Na} and Ara Ko and Maria Khim and Catherine Kim and Park, {Nung Hwa} and Song, {Ho Young} and Kim, {Seong Who} and Heuiran Lee",
year = "2012",
month = "9",
day = "1",
doi = "10.1007/s00018-012-0998-1",
language = "English (US)",
volume = "69",
pages = "3147--3158",
journal = "Cellular and Molecular Life Sciences",
issn = "1420-682X",
publisher = "Birkhauser Verlag Basel",
number = "18",

}

TY - JOUR

T1 - Multispecies-compatible antitumor effects of a cross-species small-interfering RNA against mammalian target of rapamycin

AU - Ahn, Jeonghyun

AU - Woo, Ha Na

AU - Ko, Ara

AU - Khim, Maria

AU - Kim, Catherine

AU - Park, Nung Hwa

AU - Song, Ho Young

AU - Kim, Seong Who

AU - Lee, Heuiran

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Successful development of sequence-specific siRNA (small interfering RNA)-based drugs requires an siRNA design that functions consistently in different organisms. Utilizing the CAPSID program previously developed by our group, we here designed siRNAs against mammalian target of rapamycin (mTOR) that are entirely complementary among various species and investigated their multispecies-compatible gene-silencing properties. The mTOR siRNAs markedly reduced mTOR expression at both the mRNA and protein levels in human, mouse, and monkey cell lines. The reduction in mTOR expression resulted in inactivation of both mTOR complex I and II signaling pathways, as confirmed by reduced phosphorylation of p70S6K (70-kDa ribosomal protein S6 kinase), 4EBP1 (eIF4E-binding protein 1), and AKT, and nuclear accumulation of FOXO1 (forkhead box O1), with consequent cell-cycle arrest, proliferation inhibition, and autophagy activation. Moreover, interfering with mTOR activity in vivo using mTOR small-hairpin RNA-expressing recombinant adeno-associated virus led to significant antitumor effects in xenograft and allograft models. Thus, the present study demonstrates that cross-species siRNA successfully silences its target and readily produces multispecies- compatible phenotypic alterations-antitumor effects in the case of mTOR siRNA. Application of crossspecies siRNA should greatly facilitate the development of siRNA-based therapeutic agents.

AB - Successful development of sequence-specific siRNA (small interfering RNA)-based drugs requires an siRNA design that functions consistently in different organisms. Utilizing the CAPSID program previously developed by our group, we here designed siRNAs against mammalian target of rapamycin (mTOR) that are entirely complementary among various species and investigated their multispecies-compatible gene-silencing properties. The mTOR siRNAs markedly reduced mTOR expression at both the mRNA and protein levels in human, mouse, and monkey cell lines. The reduction in mTOR expression resulted in inactivation of both mTOR complex I and II signaling pathways, as confirmed by reduced phosphorylation of p70S6K (70-kDa ribosomal protein S6 kinase), 4EBP1 (eIF4E-binding protein 1), and AKT, and nuclear accumulation of FOXO1 (forkhead box O1), with consequent cell-cycle arrest, proliferation inhibition, and autophagy activation. Moreover, interfering with mTOR activity in vivo using mTOR small-hairpin RNA-expressing recombinant adeno-associated virus led to significant antitumor effects in xenograft and allograft models. Thus, the present study demonstrates that cross-species siRNA successfully silences its target and readily produces multispecies- compatible phenotypic alterations-antitumor effects in the case of mTOR siRNA. Application of crossspecies siRNA should greatly facilitate the development of siRNA-based therapeutic agents.

KW - CAPSID

KW - Cross-species activity

KW - Mammalian target of rapamycin

KW - Small-interfering RNA

KW - Tumor therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84865658775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865658775&partnerID=8YFLogxK

U2 - 10.1007/s00018-012-0998-1

DO - 10.1007/s00018-012-0998-1

M3 - Article

C2 - 22562582

AN - SCOPUS:84865658775

VL - 69

SP - 3147

EP - 3158

JO - Cellular and Molecular Life Sciences

JF - Cellular and Molecular Life Sciences

SN - 1420-682X

IS - 18

ER -